NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TIL

Instil Bio Inc

Jun 30 • 04:00PM ET

20.83

Dollar change -2.14
Percentage change -9.32	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE ADAP IOVA EDIT CRSP PSTX BLUE BMRN SRPT CLLS

| Held by: VTI VXF DFAT IWC DFAS AVSC DFAC DFSU DFAU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.97	Insider Own	49.26%	Shs Outstand	6.56M	Perf Week	-30.19%
Market Cap	136.64M	Forward P/E	-	EPS next Y	-13.11	Insider Trans	0.00%	Shs Float	3.33M	Perf Month	-31.37%
Enterprise Value	118.70M	PEG	-	EPS next Q	-2.50	Inst Own	36.80%	Short Float	24.39%	Perf Quarter	15.21%
Income	-78.03M	P/S	-	EPS this Y	5.16%	Inst Trans	-2.55%	Short Ratio	2.90	Perf Half Y	-4.84%
Sales	0.00M	P/B	0.94	EPS next Y	-21.36%	ROA	-28.70%	Short Interest	0.81M	Perf YTD	9.11%
Book/sh	22.09	P/C	1.31	EPS next 5Y	-	ROE	-44.50%	52W High	92.00 -77.36%	Perf Year	114.74%
Cash/sh	15.95	P/FCF	-	EPS past 3/5Y	22.33% -62.10%	ROIC	-34.05%	52W Low	9.62 116.53%	Perf 3Y	-80.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.89% 16.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	36.86%	Oper. Margin	-	ATR (14)	4.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.74	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	30.33	EPS Q/Q	-15.53%	SMA20	-31.31%	Beta	2.20	Target Price	118.67
Payout	-	Debt/Eq	0.60	Sales Q/Q	-	SMA50	-6.12%	Rel Volume	0.94	Prev Close	22.97
Employees	14	LT Debt/Eq	0.58	Earnings	May 13 BMO	SMA200	-22.56%	Avg Volume	280.48K	Price	20.83
IPO	Mar 19, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-66.96% -	Trades		Volume	262,329	Change	-9.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Upgrade	Jefferies	Hold → Buy	$11 → $52
Nov-04-24	Initiated	JMP Securities	Mkt Perform
Apr-12-24	Downgrade	Jefferies	Buy → Hold	$5 → $11
Nov-01-22	Downgrade	Truist	Buy → Hold	$16 → $6
Nov-01-22	Downgrade	Cowen	Outperform → Market Perform
Aug-13-21	Initiated	Robert W. Baird	Outperform	$34
Apr-13-21	Initiated	Truist	Buy	$32
Apr-13-21	Initiated	Morgan Stanley	Equal-Weight	$24
Apr-13-21	Initiated	Cowen	Outperform

Jun-20-25 12:00PM	Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know (Zacks)
Jun-16-25 09:55AM	Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet (Zacks)
Jun-11-25 07:00AM	Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program (GlobeNewswire)
Jun-04-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice (Zacks) +15.05%
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks) +10.02%
07:00AM	Loading…
07:00AM	Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
May-30-25 07:00AM	Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -11.20%
May-29-25 12:00PM	Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +13.46%
09:55AM	Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade (Zacks)
May-23-25 07:00AM	Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago (GlobeNewswire) -14.59%
May-22-25 06:00AM	Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 (GlobeNewswire) +51.73%
May-13-25 07:00AM	Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.87%
Apr-14-25 05:57AM	Here's Why Summit Therapeutics Stock Soared 15% on Friday (Zacks) +11.78%
Mar-04-25 07:09AM	Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-25 06:15AM	Jefferies Predicts Up to ~500% Jump for These 2 Strong Buy Stocks (TipRanks)
07:00AM	Loading…
Jan-14-25 07:00AM	Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody (GlobeNewswire) +5.31%
Nov-13-24 07:00AM	Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.51%
Oct-23-24 01:01AM	Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc (GuruFocus.com) -5.27%
Sep-27-24 09:43PM	BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
07:03PM	Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc (GuruFocus.com)
Sep-25-24 04:56AM	2 Stocks Up Over 700% in 2024 That Could Soar Even Further (Motley Fool)
Sep-17-24 04:24AM	Here's Why Everyone's Talking About Summit Therapeutics (Motley Fool)
Sep-16-24 06:00AM	Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer (GlobeNewswire) -23.91%
Sep-14-24 04:56AM	Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? (Motley Fool)
Aug-13-24 10:53PM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024 (InvestorPlace)
05:00PM	Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-24 06:00AM	Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody (GlobeNewswire)
Jul-12-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +31.13%
May-10-24 01:54PM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
12:00PM	Loading…
Mar-27-24 12:00PM	What Makes Instil Bio (TIL) a New Buy Stock (Zacks)
Mar-21-24 10:52PM	TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-18-24 12:28PM	Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why (Zacks) +6.49%
Jan-16-24 08:00AM	Instil Bio Announces Strategic Update (GlobeNewswire)
Dec-13-23 10:52AM	TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023 (InvestorPlace)
10:51AM	TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023 (InvestorPlace)
Dec-05-23 05:00PM	Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split (GlobeNewswire)
Nov-13-23 05:00PM	Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.42%
Nov-06-23 07:00AM	Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting (GlobeNewswire)
Aug-31-23 09:35AM	After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL) (Zacks)
Aug-14-23 07:00AM	Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.18%
Jun-26-23 04:38PM	Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference (GlobeNewswire)
May-11-23 07:00AM	Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -7.42%
Mar-31-23 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-22-23 07:57AM	Heres Why Instil Bio (TIL) Declined in Q4 (Insider Monkey) -5.57%
Feb-17-23 07:04AM	Private equity firms account for 39% of Instil Bio, Inc.'s (NASDAQ:TIL) ownership, while institutions account for 34% (Simply Wall St.)
Jan-31-23 05:00PM	Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site (GlobeNewswire) +6.52%
Jan-09-23 12:30PM	Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers (Benzinga) +5.73%
07:00AM	Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer (GlobeNewswire)
Dec-13-22 09:35AM	Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks) -16.25%
Dec-09-22 09:35AM	Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL) (Zacks)
Dec-08-22 11:04AM	Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees (Benzinga) -19.67%
07:00AM	Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce (GlobeNewswire)
Nov-14-22 04:07PM	Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.74%
Nov-08-22 07:00AM	Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-31-22 10:40AM	Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials (Benzinga) -37.14%
08:52AM	Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials (MarketWatch)
07:00AM	Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing (GlobeNewswire)
Oct-18-22 07:00AM	Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR), in Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-19-22 07:20AM	Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -7.07%
Sep-09-22 07:00AM	Instil Bio to Present at Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer (GlobeNewswire)
Aug-12-22 07:00AM	Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-12-22 08:21AM	Will Instil Bio (NASDAQ:TIL) Spend Its Cash Wisely? (Simply Wall St.)
Jul-11-22 05:28PM	Instil Bio Life Sciences Campus in Tarzana gets $85 million loan for expansion (American City Business Journals) -6.27%
May-27-22 07:00AM	Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment (GlobeNewswire) -24.34%
May-18-22 07:00AM	Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire) -5.09%
May-16-22 07:00AM	Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.70%
Mar-07-22 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-22 07:00AM	Instil Bio to Present at the Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Nov-15-21 07:00AM	Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-10-21 11:28AM	Was The Smart Money Right About Instil Bio, Inc. (TIL)? (Insider Monkey)
Nov-08-21 08:05AM	Instil Bio to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Sep-16-21 07:00AM	Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress (GlobeNewswire)
Sep-15-21 04:27PM	Why Iovance Is Up Nearly 11% Today (Motley Fool) +16.55%
Sep-13-21 07:00AM	Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma (GlobeNewswire)
Sep-02-21 07:00AM	Instil Bio to Present at Upcoming Investor Conferences in September (GlobeNewswire) +7.49%
Aug-12-21 07:00AM	Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-19-21 02:34PM	Do Hedge Funds Love Instil Bio, Inc. (TIL)? (Insider Monkey)
Jun-21-21 10:06AM	Are Institutions Heavily Invested In Instil Bio, Inc.'s (NASDAQ:TIL) Shares? (Simply Wall St.)
Jun-01-21 07:00AM	Instil Bio to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 07:00AM	Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.83%
Apr-29-21 08:45AM	At a Recent Cancer Research Conference, Instil Bio Stole the Show (Motley Fool) +6.10%
Apr-27-21 07:00AM	Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma (GlobeNewswire)
Apr-12-21 07:18AM	Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-23-21 05:00PM	Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.95%
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading (Barrons.com)
Mar-18-21 08:26PM	Instil Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TIL

Instil Bio Inc

Upgrade your FINVIZ experience